| Literature DB >> 22177276 |
Hans-Georg Kräusslich1, Thomas Böhler1, Fabrice Tiba1, Frans Nauwelaers2, Lassana Sangaré3, Boubacar Coulibaly4.
Abstract
BACKGROUND: We wanted to explore to what extent environmental exposure to immune stimulants, which is expected to be more present in rural than in urban settings, influences T cell activation and maturation in healthy and in HIV-1-infected individuals in Burkina Faso in west Africa.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22177276 PMCID: PMC3281784 DOI: 10.1186/1758-2652-14-57
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Figure 1Flow-cytometric assessment of the percentage of naïve T cells and the expression of T cell activation markers. For the determination of naïve T cell frequencies, whole blood was stained with anti-CD4 or -CD8 together with anti-CCR7 and anti-CD45RA antibodies. Panels A and B show dot plots of CD4+ and CD8+ T cells with their respective gating of the frequencies of naïve cells as shown in the region markers. For the determination of activated T cell frequencies, whole blood was stained with anti-CD3 and anti-CD4 or anti-CD8 together with anti-CD95 or anti-CD38 antibodies, respectively. Panels C and D show histogram plots of CD4+ and CD8+ T cells expressing CD95 and CD38 activation markers, respectively. The peak of unstained control is shown in the first decade of each plot. Peaks of CD95dim and CD95bright on CD4+ cell populations were separately analyzed. The expression of CD38 on CD8+ T cells was characterized by a unique peak.
Comparison of clinical and immunological parameters between HIV-1-infected and healthy adults living in Burkina Faso
| Nouna (rural) | Ouagadougou (urban) | |||||
|---|---|---|---|---|---|---|
| n = | 61 | 26 | - | 137 | 63 | - |
| Female [n = ; (%)] | 44 (72%) | 16 (61%) | <0.0001 | 98 (72%)c | 25 (40%)* | <0.0001 |
| Age [years; median, range] | 35 (30-43) | 27 (19-35) | <0.0001 | 35 (23-48) | 28 (20-35) | <0.0001 |
| HIV-1 plasma viral load (log10 copies ml-1] | 5.8 (4.6-6.6) | n.d. | - | 5.4 (4.0-6.2)b | n.d. | - |
| CD4+ T cell count [μl-1] | 174 (33-314) | n.d. | - | 256 (118-387)b | n.d. | - |
| CDC-stage A [n = ; (%)] | 01 (02%) | n.d. | - | 22 (16%)c | n.d. | - |
| CDC-stage B [n = ; (%)] | 23 (38%) | n.d. | - | 55 (40%)c | n.d. | - |
| CDC-stage C [n = ; (%)] | 37 (60%) | n.d. | - | 60 (44%)c | n.d. | - |
All patients were "treatment-naïve", i.e., without known or reported previous exposure to single or combined antiretroviral drugs or highly active antiretroviral combination therapy (HAART). If not otherwise indicated, median values are shown with 10th and 90th percentiles in parentheses. The Mann-Whitney U-test was used to compare patients and controls in the rural and urban setting, as well as patients in the rural and urban setting and controls in the rural and the urban setting separately.
Abbreviations: p - p value for the difference between patients and controls; CDC - Centers of Disease Control and Prevention immunologic staging; n.d. - not done
ap <0.05, bp <0.001, cp <0.001 indicating statistically significant differences between HIV-1 infected subjects in Ouagadougou (urban) and HIV-1 infected subjects from Nouna (rural)
*p < 0.05; **p < 0.01; ***p < 0.001, indicating statistically significant differences between healthy controls in Ouagadougou (urban) and healthy controls in Nouna (rural)
Figure 2Percentage of naïve and activated CD4. Whisker plots were used to compare the percentages of naïve and activated CD4+ and CD8+ T cells between HIV-1 infected subjects and healthy controls from the different study sites using the Mann-Whitney U-test. Panels A and B show the comparison of the percentage of naïve CD4+ and CD8+ T cells, respectively, between HIV-1 infected subjects and healthy controls from Nouna (rural) and Ouagadougou (urban). Panels C and D show the comparison of the percentage of CD95+CD4+ and of CD38+CD8+ T cells, respectively, between HIV-1 infected subjects and healthy controls from Nouna and Ouagadougou. Symbols: (a) indicates a statistically significant difference (p < 0.05) between HIV-1 infected subjects in Ouagadougou and HIV-1 infected subjects from Nouna; (** or ***) indicates a statistically significant difference (p < 0.001 and p < 0.0001) between healthy controls in Ouagadougou and healthy controls in Nouna.
Figure 3Expression of T cell activation markers on CD4. Whisker plots were used to compare the antibody-binding capacity (ABC) of CD95+ CD4+ T cells (panel A and B) and CD38+ CD8+ T cells (panel C) between HIV-1 infected subjects and healthy controls from the different study sites using the Mann-Whitney U-test. Panel A shows data on the ABC of CD95dim CD4+ CD3+ cells, panel B on the ABC of CD95brightCD4+ CD3+ cells, and panel C shows the comparison of the ABC of CD38 CD8+ CD3+ cells between HIV-1 infected subjects and healthy controls from Nouna (rural) and Ouagadougou (urban). Symbols: (*) indicates statistically significant difference (p < 0.05) between healthy controls in Ouagadougou (urban) and healthy controls in Nouna (rural).
Figure 4T cell activation, CD4. Correlation between activation marker antibody binding capacity (ABC) of peripheral blood T cells and CD4+ T cell counts in 132 treatment-naïve HIV-1 infected patients (panels A, C and E) as well as HIV-1 plasma viral load levels in 125 patients (panels B, D and F) living in Ouagadougou, the capital of Burkina Faso. ABC was derived from the median fluorescence intensity as described in the Methods section. Panel A shows the correlation between the ABC of CD4+CD95bright T cells and CD4+ T cell counts, panel B between the ABC of CD4+CD95bright T cells and HIV-1 plasma viral load. Panel C depicts the correlation between the ABC of CD4+CD95dim T cells and CD4+ T cell counts, and panel D the correlation between the ABC of CD4+CD95dim T cells and HIV-1 plasma viral load. Panel E shows the correlation between the ABC of CD8+CD38+ T cells and CD4+ T cell counts, and panel F between the ABC of CD8+CD38+ T cells and HIV-1 plasma viral load. Correlations between variables were explored by calculation of Pearson's correlation coefficient (r) and the coefficient of determination (R2), which are indicated for each analysis.
Figure 5T cell activation, CD4. Correlation between activation marker antibody binding capacity (ABC) of peripheral blood T cells and CD4+ T cell counts (panels A, C and E), or HIV-1 plasma viral load levels (panels B, D and F) in 61 treatment-naïve HIV-1 infected patients living in Nouna, rural Burkina Faso. ABC was derived from the median fluorescence intensity as described in the Methods section. Panel A shows the correlation between the ABC of CD4+CD95bright T cells and CD4+ T cell counts, and panel B between the ABC of CD4+CD95bright T cells and HIV-1 plasma viral load. Panel C depicts the correlation between the ABC of CD4+CD95dim T cells and CD4+ T cell counts, and panel D the correlation between the ABC of CD4+CD95dim T cells and HIV-1 plasma viral load. Panel E shows the correlation between the ABC of CD8+CD38+ T cells and CD4+ T cell counts, and panel F between the ABC of CD8+CD38+ T cells and HIV-1 plasma viral load. Correlations between variables were explored by calculation of Pearson's correlation coefficient (r) and the coefficient of determination (R2), which are indicated for each analysis.